Key Stats for VKTX Stock
- Price Change for VKTX stock: +11%
- VKTX Share Price as of Feb. 23: $34.46
- 52-Week High: $43
- VKTX Stock Price Target: $92.72
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Viking Therapeutics (VKTX) stock rose about 11% after the company said it plans to advance its oral obesity drug, VK2735, into late-stage clinical trials.
According to Reuters, Viking announced the decision after reporting positive Phase 2 results for VK2735, showing meaningful weight loss and a favorable safety profile in patients with obesity.
The update came alongside Viking’s Q4 2025 earnings, where the company posted a wider net loss due to sharply higher R&D spending tied to obesity and metabolic programs.
Despite the loss, investors focused on the clinical progress because late-stage trials significantly increase a drug candidate’s commercial potential.
See analysts’ growth forecasts and price targets for VKTX stock (It’s free!) >>>
What the Market Is Telling Us About VKTX Stock
The rally suggests investors are willing to look past near-term losses and focus on Viking’s obesity pipeline. Viking ended 2025 with about $706 million in cash and short-term investments and no meaningful debt, giving it flexibility to fund late-stage trials.
However, profitability remains a major headwind. Viking reported a FY 2025 net loss of about $360 million, driven by R&D expenses that more than tripled year over year.
Margins are deeply negative, and the company has not yet generated commercial revenue, so valuation multiples such as P/E and EV/EBITDA remain negative.
Still, analysts expect long-term growth if VK2735 succeeds, which explains why the stock trades at a premium to book value despite ongoing losses.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Viking Therapeutics, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up VKTX, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track VKTX alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Viking Therapeutics stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
